Bone Biologics Q3 2025 Earnings Results & Report

Bone Biologics EPS Results

• Actual EPS: -$0.37
• Consensus EPS: -$1.23
• Beat/Miss: Beat by +$0.86
• One Year Ago EPS: N/A
• EPS Beat Rate: 4 of last 8 quarters

Bone Biologics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bone Biologics (NASDAQ:BBLG) Corporation (NASDAQ: BBLG) is a biotechnology company focused on developing regenerative medicine products for the orthopedic and spine markets. Its work centers on bone growth and spinal fusion, where physicians use biologic materials and implants to help stabilize the spine and support the formation of new bone.

The company’s primary technology is based on NELL-1, a recombinant human protein that has demonstrated bone-forming properties in preclinical and clinical research. Bone Biologics has been developing NELL-1-based products, including bone graft substitutes intended for use with spinal fusion procedures. The company’s strategy is to combine its biologic technology with established scaffold materials and delivery systems to create products designed to promote bone regeneration.

Bone Biologics has historically operated as a development-stage biotechnology company and has focused its research and commercialization efforts primarily on the United States spine and orthopedic markets. Its products remain subject to clinical development and regulatory approval, and the company has not established a broad portfolio of commercially marketed products based on the available information.